Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
Cisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship betw...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580823000031 |
| _version_ | 1811167234927624192 |
|---|---|
| author | Yuko Yamamoto Yuji Hotta Natsumi Tomita Aya Naiki-Ito Ayae Kitagawa Urara Kuboshiki Tamaki Hagita Misuzu Noda Akimasa Sanagawa Tomoya Kataoka Masahiro Kondo Yoko Furukawa-Hibi Satoru Takahashi Kazunori Kimura |
| author_facet | Yuko Yamamoto Yuji Hotta Natsumi Tomita Aya Naiki-Ito Ayae Kitagawa Urara Kuboshiki Tamaki Hagita Misuzu Noda Akimasa Sanagawa Tomoya Kataoka Masahiro Kondo Yoko Furukawa-Hibi Satoru Takahashi Kazunori Kimura |
| author_sort | Yuko Yamamoto |
| collection | DOAJ |
| description | Cisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship between CDDP-induced AKI and trace metal elements is unknown. In this study, we cultured human renal proximal tubular epithelial cells in the presence of CDDP (0, 12.5, 25, 50 μM) and analyzed the concentration of trace elements in medium after 24 h. We found that CDDP significantly increased the concentrations of zinc (Zn) and manganese (Mn) in medium and significantly decreased them in lysate. Therefore, we examined the effects of CDDP (3 mg/kg, i.p.) administration on serum and urinary Zn and Mn concentrations in rats. The results showed that urinary excretion of Zn and Mn increased in CDDP-treated rats 5 days after administration. Also, 5 days after administration, pyknosis, nuclear loss, loss of the brush border membrane, and DNA fragmentation were observed, and serum creatinine and blood urea nitrogen levels were found to be significantly increased. These data suggested that 24-h excretion of Zn and Mn might reflect on CDDP induced nephropathy. Monitoring urinary Zn and Mn excretion may be beneficial in detecting AKI, but further studies are needed for clinical application. |
| first_indexed | 2024-04-10T16:07:00Z |
| format | Article |
| id | doaj.art-56fd3104a4b1471fb42f3697499de767 |
| institution | Directory Open Access Journal |
| issn | 2405-5808 |
| language | English |
| last_indexed | 2024-04-10T16:07:00Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biochemistry and Biophysics Reports |
| spelling | doaj.art-56fd3104a4b1471fb42f3697499de7672023-02-10T04:22:48ZengElsevierBiochemistry and Biophysics Reports2405-58082023-03-0133101422Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injuryYuko Yamamoto0Yuji Hotta1Natsumi Tomita2Aya Naiki-Ito3Ayae Kitagawa4Urara Kuboshiki5Tamaki Hagita6Misuzu Noda7Akimasa Sanagawa8Tomoya Kataoka9Masahiro Kondo10Yoko Furukawa-Hibi11Satoru Takahashi12Kazunori Kimura13Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan; Department of Analytical Chemistry, Aichi Prefectural Institute of Public Health, 7-6, Nagare, Tsuji-machi, Kita-ku, Nagoya, 462-8576, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan; Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan; Corresponding author. Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan.Department of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, JapanDepartment of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan; Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan; Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanDepartment of Hospital Pharmacy, Nagoya City University Graduate School of Pharmaceutical Sciences, 3-1 Tanabe do-ri, Mizuho-ku, Nagoya, 467-8603, Japan; Department of Pharmacy, Nagoya City University Hospital, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan; Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, JapanCisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship between CDDP-induced AKI and trace metal elements is unknown. In this study, we cultured human renal proximal tubular epithelial cells in the presence of CDDP (0, 12.5, 25, 50 μM) and analyzed the concentration of trace elements in medium after 24 h. We found that CDDP significantly increased the concentrations of zinc (Zn) and manganese (Mn) in medium and significantly decreased them in lysate. Therefore, we examined the effects of CDDP (3 mg/kg, i.p.) administration on serum and urinary Zn and Mn concentrations in rats. The results showed that urinary excretion of Zn and Mn increased in CDDP-treated rats 5 days after administration. Also, 5 days after administration, pyknosis, nuclear loss, loss of the brush border membrane, and DNA fragmentation were observed, and serum creatinine and blood urea nitrogen levels were found to be significantly increased. These data suggested that 24-h excretion of Zn and Mn might reflect on CDDP induced nephropathy. Monitoring urinary Zn and Mn excretion may be beneficial in detecting AKI, but further studies are needed for clinical application.http://www.sciencedirect.com/science/article/pii/S2405580823000031CisplatinAcute kidney injuryUrineZincManganese |
| spellingShingle | Yuko Yamamoto Yuji Hotta Natsumi Tomita Aya Naiki-Ito Ayae Kitagawa Urara Kuboshiki Tamaki Hagita Misuzu Noda Akimasa Sanagawa Tomoya Kataoka Masahiro Kondo Yoko Furukawa-Hibi Satoru Takahashi Kazunori Kimura Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury Biochemistry and Biophysics Reports Cisplatin Acute kidney injury Urine Zinc Manganese |
| title | Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury |
| title_full | Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury |
| title_fullStr | Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury |
| title_full_unstemmed | Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury |
| title_short | Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury |
| title_sort | changes in zinc and manganese concentrations in cisplatin induced acute kidney injury |
| topic | Cisplatin Acute kidney injury Urine Zinc Manganese |
| url | http://www.sciencedirect.com/science/article/pii/S2405580823000031 |
| work_keys_str_mv | AT yukoyamamoto changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT yujihotta changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT natsumitomita changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT ayanaikiito changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT ayaekitagawa changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT urarakuboshiki changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT tamakihagita changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT misuzunoda changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT akimasasanagawa changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT tomoyakataoka changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT masahirokondo changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT yokofurukawahibi changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT satorutakahashi changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury AT kazunorikimura changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury |